<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01072708</url>
  </required_header>
  <id_info>
    <org_study_id>2008.523/24</org_study_id>
    <nct_id>NCT01072708</nct_id>
  </id_info>
  <brief_title>Determination of the Predictive Factors in the Reversibility or the Aggravation in the Disorders of the Glucose Metabolism in Cystic Fibrosis Patients</brief_title>
  <acronym>DIAMUCO</acronym>
  <official_title>Determination of the Predictive Factors in the Reversibility or the Aggravation in the Disorders of the Glucose Metabolism in Cystic Fibrosis Patients (Study DIAMUCO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      For some years, the investigators observe an increase of the arisen of diabetes in cystic
      fibrosis patients However, this diabetes may be reversible. The investigators speak about &quot;
      Cystic fibrosis related diabetes.&quot;. The objective of this project, is to know better what
      facilitates the appearance and the reversibility of the diabetes, such as the genetic
      mutations, the respiratory state and the lung infections. Theses knowledges should allow to
      adapt the screening of diabetes, and its treatment, for the patients affected by cystic
      fibrosis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Describe the natural history of the glucose tolerance in cystic fibrosis patients and to identify the predictive factors of the reversibility or the aggravation in the disorders of the glucidic metabolism.</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Estimate prevalence of the various stages of disorders of the glucose metabolism : glucose intolerance and diabetes</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimate the probability of arisen the complications associated to the disorders of the glucidic metabolism : - deterioration of the respiratory function, - lung exacerbations - alteration of the nutritional state</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">230</enrollment>
  <condition>Diabetes in Cystic Fibrosis Patients</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Prospective cohort with an annual follow-up</intervention_name>
    <description>Annualfollow-up including :
oral glucose tolerance test
dietary survey
biological evaluation
bacteriological and respiratory measures
dual-energy x-ray absorptiometry
physical activity survey</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cystic fibrosis patients with at least one visit in Cystic fibrosis Center in
             Rhône-Alpes (France) during the second half-year 2008

          -  Patients with disorders or not of the glucose metabolism

          -  Patient with pancreatic insufficiency

        Exclusion Criteria:

          -  Patient with hypoglycemia treatment : insulin or oral antidiabetic

          -  Patient with an age &lt; 10 years

          -  Patient with lung transplant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Service de Médecine Interne - Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Reynaud Q, Rabilloud M, Roche S, Poupon-Bourdy S, Iwaz J, Nove-Josserand R, Blond E, Laville M, Llerena C, Quetant S, Reix P, Touzet S, Durieu I. Glucose trajectories in cystic fibrosis and their association with pulmonary function. J Cyst Fibros. 2018 May;17(3):400-406. doi: 10.1016/j.jcf.2017.09.010. Epub 2017 Oct 14.</citation>
    <PMID>29037538</PMID>
  </results_reference>
  <verification_date>February 2016</verification_date>
  <study_first_submitted>February 19, 2010</study_first_submitted>
  <study_first_submitted_qc>February 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2010</study_first_posted>
  <last_update_submitted>May 23, 2019</last_update_submitted>
  <last_update_submitted_qc>May 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cystic fibrosis -diabetes - glucose tolerance - reversibility - oral glucose tolerance test - predictive factors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

